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Abstract
Background: Sodium retention and ascites are serious clinical problems in cirrhosis. Urodilatin
(URO) is a peptide with paracrine effects in decreasing sodium reabsorption in the distal nephron.
Our aim was to investigate the renal potency of synthetic URO on urine sodium excretion in
cirrhosis patients with sodium retention and ascites.
Methods: Seven cirrhosis patients with diuretics-resistant sodium retention received a short-term
(90 min) infusion of URO in a single-blind, placebo-controlled cross-over study. In the basal state
after rehydration the patients had urine sodium excretion < 50 mmol/24 h.
Results: URO transiently increased urine sodium excretion from 22 ± 16 μmol/min (mean ± SD)
to 78 ± 41 μmol/min (P < 0.05) and there was no effect of placebo (29 ± 14 to 44 ± 32). The
increase of URO's second messenger after the receptor, cGMP, was normal. URO had no effect
on urine flow or on blood pressure. Most of the patients had highly elevated plasma levels of renin,
angiotensin II and aldosterone and URO did not change these.
Conclusion: The short-term low-dose URO infusion increased the sodium excretion of the
patients. The increase was small but systematic and potentially clinically important for such patients.
The small response contrasts the preserved responsiveness of the URO receptors. The markedly
activated systemic pressor hormones in cirrhosis evidently antagonized the local tubular effects of
URO.
Background
Sodium and water retention occurring in decompensated
cirrhosis and leading to ascites is a clinical challenge and
may be difficult to treat [1-3]. Therapeutic possibilities
include sodium restriction, diuretics and aldosterone
antagonists, and in refractory cases repeated paracentesis,
transjugular intrahepatic porto-systemic shunt (TIPS), or
liver transplantation. Further pathophysiological insight
and new treatment modalities are desirable. Any new drug
with the potential of increasing sodium and water excre-
tion in cirrhosis patients with refractory ascites and severe
sodium retention will be a significant clinical improve-
ment for this group of patients.
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The atrial natriuretic peptide (ANP) has been investigated
as such an alternative agent, but the benefits were quite
modest [4-7]. Our group in previous works focused on the
renal effects of synthetic urodilatin (URO), another mem-
ber of the natriuretic peptide family, with dose-dependent
renal effects in normal man [8,9]. Endogenous URO is the
product of a different posttranslational processing of pro-
ANP that takes place in the distal tubule cells. URO
released into the tubular lumen stimulates natriuretic
peptide receptors on the luminal surface of tubular cells
and thereby inhibits distal tubular sodium reabsorption
[10]. Specific guanylate cyclase-coupled receptors in the
inner medullary collecting ducts are the physiological tar-
get sites for URO and cGMP is the second messenger for
URO's biological actions. [11,12]. Thus, URO is an intra-
renal paracrine regulator of sodium and water homeosta-
sis. Urine urodilatin excretion is normal in patients with
cirrhosis even in the presence of marked sodium reten-
tion. The coexistence of increased ANP levels and normal
urodilatin excretion suggests that in cirrhosis the two
natriuretic peptides are regulated independently [13].
In patients with cirrhosis and light to moderate sodium
retention we earlier showed that administration of syn-
thetic URO more than doubled natriuresis and increased
diuresis due to enhanced fluid delivery from the proximal
tubules, and in addition, inhibited fractional sodium rea-
bsorption in the distal nephron, as demonstrated by lith-
ium clearance [14].
The aim of this study was to investigate the natriuretic and
diuretic effects of synthetic URO in cirrhosis patients with
severe sodium retention and ascites refractory to conven-
tional diuretic therapy.
Methods
Patients
The inclusion criteria were: (1) presence of cirrhosis in a
liver biopsy; (2) or anamnestic, clinical and laboratory
evidence of cirrhosis including ascites (verified by ultra-
sound), oesophagogastric varices (verified by gastros-
copy), hypoalbuminemia and reduced prothrombin
index; (3) a 24-h urine sodium excretion <60 mmol; and
(4) written informed consent. The exclusion criteria were:
(1) primary kidney disease (s-creatinine > 200 μmol/L);
(2) congestive heart failure; (3) diabetes; (4) haemo-
globin < 6.0 mmol/L; and (5) a history of bladder dys-
function. The withdrawal criteria during or after the study
were: (1) severe adverse events during or after URO, and
(2) lack of urination at the appointed time points.
Seven cirrhosis patients with ascites refractory to pharma-
cotherapy were consecutively recruited in our department.
Their mean age was 54 ± 7 years (mean ± SD), mean body
weight 69 ± 13 kg; five men and two women. Three
patients had cirrhosis verified by a liver biopsy. Four
patients had oesophagogastric varices. All the patients had
alcoholic liver disease. The basal characteristics of the
patients including their MELD score are summarized in
Table 1. All patients received diuretics as a combination
therapy of spironolactone and furosemide. The patients
had their diuretic treatment and hydration status adjusted
in the time period between enrolment and the first study
infusion day. The patients had normal ECG. Plasma-creat-
inine was 67 ± 19 μmol/L.
Informed written consent was obtained from all patients,
and the study was approved by the local Ethics Commitee
of Aarhus and the Danish National Board of Health; and
Table 1: The basal characteristics of the 6 patients included in the statistical analysis.
No. 1 No. 2 No. 3 No. 4 No. 5 No. 6
[unit/reference interval] Male Male Female Male Male Female
Total Plasma Bilirubin [< 22 micromol/L] 33 549 35 33 17 38
Plasma Albumin [551–725 micromol/L] 366 445 330 506 272 294
PP [0.80–1.20 arbitrary units] 0.55 0.20 0.30 0.66 0.42 0.39
Ascites yes yes yes yes yes yes
Encephalopathy no no no no no no
MELD score [5–15 points] 6 27 9 6 6 9
Plasma Sodium [136–146 mmol/L] 132 134 140 135 125 132
Plasma Creatinine [55–120 micromol/L] 105 50 62 85 52 58
Urine Sodium/24 hours [mmol/24 h] 10 35 27 48 35 31
UNa (baseline) [μmol/min] URO 3.1 Pl. 6.7 URO 28.1 Pl. 14.8 URO 36.7 Pl. 37.0 URO 22.5 Pl. 41.4 URO 44.0 Pl. 40.0 URO 18.7 Pl. 34,7
V (baseline) [mL/min] URO 0.44 Pl. 1.04 URO 0.35 Pl. 0.44 URO 1.20 Pl. 1.77 URO 0.74 Pl. 0.90 URO 1.18 Pl. 1.65 URO 0.93 Pl. 1.93
Serum Renin [10–70 mIU/L] 273 527 19 371 104 545
Serum Angiotensin II [10–30 pmol/L] 97 100 6 42 33
Serum Aldosterone [40–500 pmol/L] 5363 1419 287 171 306 1768
Systemic Blood Pressure [mmHg] 95/60 112/65 100/60 112/65 105/80 100/65
Furosemide [mg/24 hours] 80 40 40 120 80 80
Spironolactone [mg/24 hours] 200 200 200 200 200 200
URO = urodilatin. Pl. = placebo. UNa = urine sodium excretion rate. V = urine flow rate. PP = prothrombin time. MELD = Model of End-stage Liver 
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it was performed in accordance with the Declaration of
Helsinki.
Design
It was a randomised, single-blind, placebo-controlled
study with synthetic urodilatin (Boehringer Mannheim
GmbH, Mannheim, Germany). Each patient participated
on two study days. Each patient received, in a randomised
order, a 90-min infusion of URO (20 ng kg body weight-1
min-1) and a 90-min infusion of placebo (PL). It thus was
a cross-over design with a wash-out period of 2–3 days.
The lyophilised URO was dissolved in isotonic saline
solution. Placebo was isotonic saline. Infusions were
given by pump at a rate of 0.2 ml kg-1 h-1. In a patient of
eg 70 kg bodyweight, the total infusion volume was 21
mL. The URO dose was chosen from previous observa-
tions with a threshold dose of 20 ng kg body weight-1 min-
1 and risk of side effects with higher doses [8].
Procedures
All patients were hospitalised during the study. A 24-h
urine sample was collected before enrolment. There was a
run-time of four to 14 days during which diuretic treat-
ment was adjusted and stabilized, and it was discontinued
the day before infusion of both URO and placebo, but
continued in between the two study days. The patients
fasted from midnight and took notes of the time points of
last urination before sleep and morning urination, and
the urine volume including nightly urine was measured
(clearance period 1). On the study day, 200 mL of water
was given orally every 30 min from 7:30 am till noon. The
study comprised a pre-infusion phase of 90 min (7:30 am
to 9 am; clearance period 2), the infusion phase of 90 min
(9 am to 10:30 am; clearance periods 3 and 4) and a post-
infusion phase of 90 min (10:30 am to noon; clearance
periods 5 and 6). Urine was collected in consecutive 45-
min clearance periods from 9 am. The morning urine and
urine collected at 9 am were used as baseline (clearance
periods 1 and 2). At 9 am, infusion was initiated. The
patient was in supine position, except during urination,
which took place in upright position.
Urine samples from the 24-h urine and clearance periods
were analysed for sodium and potassium contents. At the
beginning and end of each clearance period, venous
blood samples were drawn for concentrations of sodium,
renin, angiotensin II (AngII), aldosterone (Aldo), and
cyclic guanosine monophosphate (cGMP). Blood was
secured in the supine position and before urination and
followed by administration of the same volume of isot-
onic saline i.v. Systemic blood pressure (BP) and heart
rate (HR) were measured every 20 min from 8 am till
noon.
Methods
Plasma sodium (PNa) and creatinine and urine sodium
(UNa), potassium (UK) were determined by an autoana-
lyser (local Department of Clinical Biochemistry). Serum
AngII, Aldo, renin and cGMP were determined by RIAs as
described in detail earlier [8-10].
Statistical analysis
We investigated seven patients and one of these was
excluded from data analysis due to incomplete urine col-
lection during the study day. Data not showing normal
distribution within the same group was analysed by non-
parametric Friedmans ANOVA test followed by non-para-
metric Willcoxon paired samples test. For unpaired com-
parisons between the URO and the placebo group non-
parametric Kruskall-Wallis ANOVA test was used followed
by the ManWhitney test. The differences between groups
were based on the relative changes (Δ) from pre-infusion
levels. A P-value of 0.05 was the limit of significance.
Mean values ± SD of the absolute and relative changes (Δ)
from pre-infusion levels are presented. Pearson correla-
tion coefficient was used to measure the relationship
between two variables.
Results
Urine sodium excretion rate (UNa)
The average 24-hour urine sodium excretion rate (UNa)
was 35 ± 10 mmol/day (or 24 ± 9 umol/min) before study
start. UNa baseline values are shown in Table 1. On aver-
age, URO increased UNa from 22 ± 16 μmol/min (mean ±
SD) to 78 ± 41 μmol/min (P < 0.05) while there was no
significant effect of placebo (29 ± 14 to 44 ± 32) (fig. 1).
At the end of the study, there was no difference between
URO and placebo (fig. 2). The relative changes, ΔUNa,
from baseline following URO infusion, tripled in period 3
(P = 0.10) and rose 6-fold (P = 0.05) in period 4, with very
large variation. Placebo had no appreciable effect (fig 2).
Total sodium excretion during URO and placebo infu-
sions is shown in Figure 3.
Urine flow rate (V)
V baseline values are shown in Table 1. On average, URO
increased V from 0.81 ± 0.36 ml/min to 2.95 ± 2.54 ml/
min, while placebo increased V from 1.29 ± 0.58 ml/min
to 2.36 ± 2.45 ml/min. The relative change in urine flow
after URO was marginally larger than after placebo in
period 3 (URO, 240 ± 258 %; PL, 13 ± 60%; P = 0.07), but
not in period 4 (URO, 337 ± 373%; PL, 52 ± 110%; P =
0.18), see Figure 4. Following infusion stop, V tended to
decrease on the URO day compared to Placebo (P = 0.1).
Second messenger cGMP
URO infusion markedly increased serum cGMP (P < 0.01)
(fig. 5).BMC Gastroenterology 2007, 7:1 http://www.biomedcentral.com/1471-230X/7/1
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The second messenger cGMP response was linked to the
infusion of URO, but the serum level of cGMP achieved
was independent of the level of urine sodium output, see
Figure 6.
Serum renin, angiotensin II and aldosterone
Pre-infusion concentrations of renin, AngII and Aldo in
serum are shown in Table 1. All except one patient had
highly elevated hormone levels compared to values meas-
ured in normal man [9]. Neither infusions changed any of
these levels (data not shown). There was no significant
inverse correlation between the baseline hormone levels
and the natriuretic response to URO (fig. 7, 8, 9). How-
ever, the highest urine sodium output was measured in
the only patient who had normal baseline concentration
levels of all three hormones.
Systemic Blood Pressure (BP), Heart Rate (HR) and body 
weight
There was no significant difference in changes in these var-
iables between URO and placebo infusions. There was a
minor decrease of body weight both days.
Adverse effects
One patient complained of dryness in the mouth, and
another vomited once in the post-infusion phase of URO.
One patient had a gradual drop in BP from 95/55 to 65/
50 mmHg after 85 min of URO infusion. The infusion was
completed, and the patient recovered in Trendelenburg.
Discussion
The main finding of the present study was that short-term
synthetic URO infusion induced increased natriuresis in
cirrhosis patients with severe sodium retention. The effect
was much smaller than in our previous studies in healthy
subjects and patients with less advanced cirrhosis and
Relative changes (%) in urine sodium excretion rate (UNa)  before (0 min), during (45 and 90 min), and after (135 and  180 min) infusion of URO and placebo in the 6 patients with  severe sodium retention Figure 2
Relative changes (%) in urine sodium excretion rate (UNa) 
before (0 min), during (45 and 90 min), and after (135 and 
180 min) infusion of URO and placebo in the 6 patients with 
severe sodium retention. Boxplots represent the interquar-
tile range and whiskers represent highest and lowest values. * 
P = 0.05 URO end of infusion period compared to baseline.
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minor sodium retention [8,9,14]. The cGMP response to
URO was normal.
In the previous study we demonstrated increased delivery
of isotonic fluid from the proximal tubule and decreased
fractional distal tubular sodium reabsorption during a
URO-infusion, using the lithium clearance technique
[14]. URO probably inhibited isotonic fluid reabsorption
in the proximal tubule. Still, the mechanism of action of
URO in the proximal nephron is unclear since proxinal
tubule cells do not exhibit a cGMP response. The present
investigation, in being a bed-side study, did not adopt
radioactive tracers or the lithium clearance technique to
delineate the tubular site of action of URO; we assume
that the increased natriuresis was a result of both proximal
and distal tubular action, as in our previous study.
The reason why the natriuretic response was weaker in the
patients with refractory ascites is not clarified. Obvious
differences between the patients with refractory ascites
and less advanced cirrhosis are the high plasma levels of
the anti-natriuretic hormones like renin, angiotensin II
and aldosterone. The proximal tubular action of these
anti-natriuretic hormones probably diminished distal
tubular sodium delivery to the specific guanylate cyclase-
coupled receptors in the inner medullary collecting ducts,
the main target sites of URO. This is supported by the nor-
mal cGMP response. Likewise, the same hormones prob-
ably also antagonized the inhibitory effect of URO on
isotonic fluid reabsorption in the proximal tubules. Both
mechanisms would restrict normal tubular effects of
URO.
The natriuretic effect of URO is mediated by cGMP,
released from the URO receptor. The response of this sec-
ond messenger was similar to the level measured after
administration of synthetic URO in healthy subjects and
in patients with less advanced cirrhosis [8,14]. This indi-
cates intact biological responsiveness of the URO recep-
tors in severe sodium retainers, including peptide receptor
coupling and intracellular URO signalling. The normal
cGMP responses both in patients with normal and
decreased sodium excretion point to dissociation between
the biochemical (cGMP) and the physiologic (natriuresis)
Relative changes (%) in urine flow rate (U-Vol) before (0  min), during (45 and 90 min), and after (135 and 180 min)  infusion of URO and placebo in the 6 patients with severe  sodium retention Figure 4
Relative changes (%) in urine flow rate (U-Vol) before (0 
min), during (45 and 90 min), and after (135 and 180 min) 
infusion of URO and placebo in the 6 patients with severe 
sodium retention. Boxplots represents the interquartile 
range and whiskers represent highest and lowest values.
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cebo is depicted for each patient.
Total sodium excretion in urine during
infusion of URO and placebo in the 6 patients
T
o
t
a
l
 
U
N
a
 
d
u
r
i
n
g
 
U
R
O
 
i
n
f
u
s
i
o
n
 
(
u
m
o
l
)
0
2000
4000
6000
8000
10000
12000
14000
16000
Placebo
URO
123456
the 6 patientsBMC Gastroenterology 2007, 7:1 http://www.biomedcentral.com/1471-230X/7/1
Page 6 of 9
(page number not for citation purposes)
response to URO. This is in line with the prevention by the
pressor hormones of urine sodium reaching the URO site
of action. Still, we found no relation between the level of
these hormones and the natriuretic effect of URO in our
patients, but this was probably due mostly to the small
number of patients.
In the present study the effects of URO on urine flow were
highly variable but the overall impression was that URO
tended to increase diuresis (fig. 3). This is in accordance
with the mode of action of the peptide where water and
sodium handling are coupled. In the same way as regard-
ing natriuresis, the aquaretic effect of URO was much
larger and more consistent in cirrhosis patients with less
sodium retention [14].
The demonstrated renal pharmacodynamic effects of
URO were short-lived (fig. 2) because of the short half-life
(about 5 min) of URO. Therefore, there is also no reason
to suspect a carry-over effect between study days.
We used a dose of 20 ng URO kg-1 min-1 since higher doses
may lower systemic blood pressure [8,9]. Accordingly,
there was no appreciable effect on blood pressure. Adverse
effects were minor except in one patient with a moderate
fall of systolic blood pressure at the end of the URO infu-
sion. A similar low frequency of adverse effects was
observed in our previous study [14].
The patients continued on their adjusted medication and
their usual fluid and food intake until the day before study
start in order to study them in a clinically and physiolog-
ically stable phase, and also to minimize the discomforts
of taking part in a study. The patients were not placed on
a sodium controlling diet, but the identical baseline (pre-
infusion) levels of urine sodium excretion on both study
days suggest that the patients were in adequately stable
sodium equilibrium. We stopped their diuretics first on
the day before the infusion of either URO or placebo so
Corresponding values of serum cGMP and total sodium  excretion in urine after 90 min of URO infusion Figure 6
Corresponding values of serum cGMP and total sodium 
excretion in urine after 90 min of URO infusion. There was 
no significant correlation between the two variables.
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that spironolactone and its metabolites may still have
antagonized the tubular action of aldosterone and
increased the delivery of sodium to the distal nephron and
the site of action of URO and contributed to the increase
in natriuresis. The cross-over design with an interval of
two-three days between infusions likely, however,
ensured identical conditions on both study days.
The mild increase of sodium excretion rate in the placebo
group is well-known in clearance studies with water-
loaded subjects. It is of no importance in healthy subjects
responding vividly to URO, but it calls for special care in
the interpretation of the natriuretic effect of URO in the
presented sodium retainers.
The clinical implications of URO are not clarified. Stimu-
lation of the sympathetic nervous system and activation of
the renin-angiotensin-aldosterone system play a pivotal
role in the resistance to conventional diuretics in
advanced cirrhosis. As mentioned above, similar forces
are most likely the cause of the relative resistance to URO.
Maneuvres that increase distal tubular sodium delivery
may restore the renal responsiveness to URO in advanced
cirrhosis. If so, URO is not potent alone, but may be so in
combination with loop of Henle diuretics and distal tubu-
lar diuretics.
We are aware of the limitations of the study as a result of
the small number of patients. Larger trials are needed to
confirm the results before it is possible to discuss the clin-
ical use of URO in cirrhosis patients. The clinical value of
URO has been investigated in other diseases and mostly
with disappointing outcomes. URO was found to have no
beneficial effect in acute renal failure or in prevention of
renal impairment following liver transplantation [15,16].
In a recent study on decompensated chronic heart failure
a 24-hour infusion of URO substantially decreased car-
diac filling pressure because of the vasodilatory effects,
but no improved renal function was reported [17].
The URO infusion transiently shifted our patients from a
stage with threatening hepatorenal syndrome to a stage
Corresponding values of baseline serum angiotensin II and  total sodium excretion in urine after 90 min of URO infusion Figure 8
Corresponding values of baseline serum angiotensin II and 
total sodium excretion in urine after 90 min of URO infusion. 
There was no significant inverse correlation between the 
two variables.
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with controllable salt balance. Although the demon-
strated natriuretic effect was physiologically small, it may
nonetheless be clinically important by lifting the patients
over the threshold of irreversible decompensation. Alter-
natively, the results can be taken to show that the mecha-
nisms that favour sodium excretion seem to be operative
if the sodium retaining systems can be de-activated.
Conclusion
These patients with decompensated cirrhosis and severe
sodium retention responded systematically but modestly
to a short-term low-dose URO infusion compared to the
large natriuretic response observed in previous studies
with healthy subjects and patients with less advanced cir-
rhosis. The only small natriuretic and diuretic response
contrasted the preserved biologic responsiveness of the
URO receptors in the inner medullary collecting ducts.
This was probably due to the activation of the systemic
mechanisms behind sodium and water retention in cir-
rhosis, evidently antagonizing the tubular effects of URO.
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